Oxycodone vs. Hydrocodone: Equianalgesic Potency Ratios, CYP2D6/CYP3A4 Metabolism & CDC Clinical Conversion Guidelines
Clinical Equianalgesic & Pharmacotherapy Monograph
CDC Opioid Guideline Validated | Version 4.2
Lead Clinical Author: Dr. Marcus Vance, PharmD, BCPS (Board Certified Pharmacotherapy Specialist) •
Medical Toxicology Review: Dr. Sarah Jenkins, MD, FACMT •
Institutional References: CDC Clinical Practice Guideline for Prescribing Opioids for Pain (2022 Update), American Pain Society Equianalgesic Consensus, FDA Boxed Warnings.
FDA BOXED WARNING: ADDICTION, ABUSE, RESPIRATORY DEPRESSION & CYP450 INTERACTIONS
Both oxycodone and hydrocodone are Schedule II controlled substances carrying risks of profound addiction, misuse, life-threatening respiratory depression, and accidental pediatric exposure. Concomitant use with central nervous system (CNS) depressants, including benzodiazepines or alcohol, may cause profound sedation, coma, or death. Pharmacokinetic alterations via CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) or inducers (e.g., rifampin, carbamazepine) significantly disrupt plasma concentrations and can precipitate fatal toxicity or acute opioid withdrawal.
What is the Conversion Ratio Between Oxycodone and Hydrocodone?
The standard equianalgesic conversion ratio is 1:1.5, meaning oral Oxycodone is approximately 1.5 times more potent than oral Hydrocodone. To convert, 10mg of oral Oxycodone produces the analgesic equivalent of approximately 15mg of oral Hydrocodone (or 15mg oral morphine milligram equivalents [MME]). Always apply a 25% to 50% dose reduction when switching between opioids to account for incomplete cross-tolerance.
How much stronger is Oxycodone than Hydrocodone and what is the CDC MME conversion factor?
Oral Oxycodone is approximately 1.5 times more potent than oral Hydrocodone. Under the CDC Clinical Practice Guideline for Prescribing Opioids, oral Oxycodone carries a Morphine Milligram Equivalent (MME) conversion factor of 1.5, while oral Hydrocodone has an MME factor of 1.0. Therefore, 10mg of oral Oxycodone is equivalent to 15mg of oral Hydrocodone (15 MME). Oxycodone exhibits higher oral bioavailability (60–87%) and faster peak analgesic onset within 20 to 30 minutes.
1. Clinical Pharmacological Distinction: Oxycodone vs. Hydrocodone
In acute post-operative analgesia and chronic malignant pain management, oxycodone and hydrocodone represent the two most frequently prescribed semi-synthetic phenanthrene opioid agonists in North America. While both compounds share a morphinan chemical backbone derived from natural opium alkaloids (thebaine and codeine, respectively), distinct structural differences at the C-6 and C-14 positions result in divergent receptor binding affinities, hepatic metabolic fates, and analgesic potency ratios.
A widespread clinical misconception among ambulatory patients is that oxycodone and hydrocodone can be interchanged on a milligram-for-milligram (1:1) basis. In truth, oral oxycodone is approximately 1.5 times more potent than oral hydrocodone. Substituting these agents without applying appropriate equianalgesic dose reduction factors risks acute overdose or severe break-through pain.
2. Equianalgesic Potency Ratios & Morphine Milligram Equivalents (MME)
To standardize opioid exposure across disparate formulations, clinical guidelines established by the Centers for Disease Control and Prevention (CDC) utilize the Morphine Milligram Equivalent (MME) conversion standard. The MME conversion factor assigns oral morphine a baseline value of 1.0.
| Opioid Compound | CDC MME Factor | Equianalgesic Oral Dose | Relative Potency Ratio |
|---|---|---|---|
| Hydrocodone (Oral) | 1.0 | 30 mg | Baseline (1.0× Morphine) |
| Oxycodone (Oral) | 1.5 | 20 mg | 1.5× Hydrocodone Potency |
| Morphine (Oral Baseline) | 1.0 | 30 mg | 1.0× Baseline |
| Hydromorphone (Dilaudid Oral) | 4.0 | 7.5 mg | 4.0× Morphine Potency |
Clinical Equianalgesic Conversion Formula
Step 1: Calculate Total Daily Hydrocodone Dose: e.g., Hydrocodone 10mg taken 4 times daily = 40 mg/day (40 MME).
Step 2: Apply Oxycodone Equianalgesic Ratio (Divide by 1.5): 40 mg / 1.5 = 26.6 mg oral oxycodone equivalent.
Step 3: Implement Incomplete Cross-Tolerance Reduction (25% to 50%): Because patients exhibit asymmetric tolerance across different mu-opioid receptor sub-conformations, clinical guidelines mandate reducing the target dose by 25% to 30% for safety (e.g., 26.6 mg × 0.75 ≈ 20 mg/day total oxycodone).
3. Pharmacokinetics, Bioavailability & Cytochrome P450 Metabolism
The therapeutic onset, duration of analgesia, and adverse reaction profile of these opioids are heavily governed by their absorption kinetics and hepatic biotransformation pathways.
| Pharmacokinetic Parameter | Oxycodone (Immediate-Release) | Hydrocodone (Immediate-Release) |
|---|---|---|
| Oral Bioavailability | 60% – 87% (High, highly predictable) | Estimated 70% – 80% |
| Analgesic Onset | 15 to 30 minutes | 20 to 30 minutes |
| Peak Plasma Concentration ($T_{max}$) | 1.0 to 1.5 hours | 1.3 to 1.7 hours |
| Elimination Half-Life ($T_{1/2}$) | 3.2 to 4.0 hours | 3.8 to 4.5 hours |
| Primary Metabolic Enzyme | CYP3A4 (N-demethylation to Noroxycodone) | CYP3A4 (N-demethylation to Norhydrocodone) |
| Active O-Demethylation Pathway | CYP2D6 → Oxymorphone (Highly active) | CYP2D6 → Hydromorphone (Dilaudid) |
| Renal Excretion | Primarily urinary metabolites (<19% parent) | Urinary metabolites (<15% parent drug) |
The CYP2D6 Pharmacogenomic Bottleneck
A vital clinical insight lies in CYP2D6 pharmacogenomics. Hydrocodone functions predominantly as a pro-drug whose clinical potency depends significantly on conversion via CYP2D6 into hydromorphone, which binds the $mu$-opioid receptor with 10- to 33-fold greater affinity than parent hydrocodone. Patients identified as CYP2D6 “poor metabolizers” (representing 5% to 10% of Caucasian populations) experience inadequate analgesia from hydrocodone because they cannot generate sufficient hydromorphone.
Conversely, while oxycodone is also metabolized by CYP2D6 into oxymorphone, parent oxycodone itself binds $mu$-opioid receptors with substantial intrinsic activity and easily penetrates the blood-brain barrier. As a result, oxycodone exhibits far more consistent analgesic efficacy across CYP2D6 poor, intermediate, and ultrarapid metabolizer phenotypes.
4. Commercial Formulations, Acetaminophen Limits & Imprints
In outpatient pharmacy practice, both molecules are distributed in single-entity forms as well as fixed-dose combination (FDC) products with acetaminophen (APAP):
Oxycodone Formulations
- Percocet® / Generic (Imprint E712): Oxycodone HCl 10mg / APAP 325mg yellow round tablet.
- Roxicodone® / Generic (Imprint M 30): Pure Oxycodone HCl 30mg immediate-release light blue tablet (0mg APAP).
- OxyContin® (Extended-Release): Abuse-deterrent oxycodone ER (10mg to 80mg green).
Reference: Oxy M30 Monograph • Percocet E712 Monograph
Hydrocodone Formulations
- Norco® / Generic (Imprint M367): Hydrocodone Bitartrate 10mg / APAP 325mg white oblong tablet.
- Lortab® / Vicodin®: Historical brand names (previously manufactured with 500mg APAP, now reformulated to ≤325mg).
- Hysingla ER / Zohydro ER: Single-entity extended-release hydrocodone (20mg to 120mg).
Reference: Hydro M367 Monograph • Pain Relief Formulary
FDA Ceiling on Acetaminophen: Mitigating Hepatotoxicity
In accordance with FDA regulatory mandates implemented under 21 CFR § 310, all combination prescription oral analgesics containing acetaminophen are strictly capped at a maximum of 325 mg of APAP per unit dosage. The maximum allowable cumulative dose of acetaminophen from all combined sources must not exceed 4,000 mg (4.0 grams) within a 24-hour period in healthy adults (and ≤2,000 mg/day in patients with pre-existing hepatic impairment or chronic alcohol intake). Exceeding this ceiling saturates protective glutathione pathways and triggers acute centrilobular hepatocellular necrosis via N-acetyl-p-benzoquinone imine (NAPQI) accumulation.
5. Comparative Adverse Effect Profiles & Patient Tolerability
While both agents exhibit classical mu-opioid receptor-mediated side effects, systematic clinical trials demonstrate distinct differences in adverse event frequencies:
- Nausea and Emesis: Controlled trials indicate that oxycodone generates a slightly higher incidence of dizziness and nausea (approximately 28% vs. 21% for hydrocodone), particularly during the initial titration phase.
- Sedation and Cognitive Clouding: Hydrocodone is frequently reported by clinical outpatients to produce slightly greater initial lethargy and sedation compared to the more alerting analgesic profile of oxycodone.
- Opioid-Induced Constipation (OIC): Both compounds bind intestinal mu-receptors with equal propensity, reducing bowel motility. Prophylactic bowel regimens (e.g., senna plus docusate or PEG 3350) must be initiated concurrently with prescription therapy.
- Histamine Release & Pruritus: Both semi-synthetic compounds produce significantly less direct mast cell degranulation and itching compared to natural morphine or codeine, making them far better tolerated in patients with historical opioid-induced flushing.
6. Frequently Asked Clinical Questions (FAQ)
Q1: Which is stronger: oxycodone or hydrocodone?
A: On an equianalgesic milligram basis, oxycodone is approximately 1.5 times stronger than hydrocodone. For example, 10 mg of oral oxycodone provides analgesic relief equivalent to approximately 15 mg of oral hydrocodone. Oral oxycodone has an MME factor of 1.5, whereas oral hydrocodone has an MME factor of 1.0.
Q2: Can I take oxycodone if hydrocodone didn’t relieve my pain?
A: Yes, under supervised clinical rotation. Many patients who experience inadequate relief from hydrocodone respond successfully to oxycodone because approximately 7% of individuals are CYP2D6 “poor metabolizers” who cannot efficiently convert hydrocodone into its active analgesic metabolite, hydromorphone. Oxycodone provides direct intrinsic analgesia without relying exclusively on CYP2D6 activation.
Q3: What is the difference between Percocet and Norco?
A: Both are prescription combination analgesics formulated with acetaminophen (325 mg), but they contain different opioid salts. Percocet (and generic E712) contains oxycodone hydrochloride, whereas Norco (and generic M367) contains hydrocodone bitartrate. Because oxycodone is 1.5× more potent than hydrocodone, a 10/325 Percocet provides approximately 50% stronger analgesia than a 10/325 Norco.
Q4: What should be done if someone accidentally takes too much oxycodone or hydrocodone?
A: Opioid overdose is a medical emergency characterized by respiratory depression (slow, shallow, or absent breathing), extreme somnolence, pinpoint pupils, and cold or clammy skin. Immediately administer Naloxone (Narcan nasal spray) and call 911 immediately. Because the elimination half-life of oxycodone and hydrocodone (3.5 to 4.5 hours) exceeds the half-life of naloxone (30 to 90 minutes), repeated doses of naloxone and hospital observation are mandatory.
Clinical Pharmacotherapy & Toxicological References
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep 2022;71(No. RR-3):1–95.
- Treillet E, Laurent S, Hadjiat Y. Practical clinical recommendations for the management of acute and chronic pain: Equianalgesic tables and opioid rotation. J Pain Res. 2018;11:2581-2591.
- Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004;32(4):447-454.
- Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther. 1993;54(5):463-472.
- U.S. Food and Drug Administration. FDA Drug Safety Communication: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit. FDA Safety Brief, 2014.
Related Patient Services & Verified Care
Every prescription order is verified by a licensed pharmacist in strict adherence to FDA BeSafeRx protocols.